Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jul 31, 2025
Reporting period
Not applicable
Filed with the SEC
Apr 20, 2026
10% ownerOption exercise
Context
Classification
option exercise
Code C — exercise or conversion of a derivative security
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001628280-26-026014
Filed / recorded
Apr 20, 2026, 8:36 PM UTC
Added to OQRO
Oct 8, 2026, 1:28 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
TriSalus Life Sciences, Inc.
Issuer CIK
1826667
Ticker
TLSI
Reporting person
Frankenius Equity AB
Relationship
10% owner
Security
Series A Convertible Preferred Stock
Table
Derivative (Table II)
Transaction date
Jul 31, 2025
Transaction code
C
Shares / units
230,000
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents conversion price pursuant to an offer (the "Offer") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share.
On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer.
A Trisalus Life Sciences director paid $25K out of pocket for Trisalus Life Sciences shares. 4 other people at Trisalus Life Sciences bought some too, in the same month. Shares held went up 16% with this purchase.
The CEO of Trisalus Life Sciences paid $103K out of pocket for Trisalus Life Sciences shares. 4 other people at Trisalus Life Sciences bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.